

Media Release: Sydney, Australia. 18 May, 2020.

PHEBRA SIGNS INTERNATIONAL DISTRIBUTION AGREEMENT FOR MANUFACTURE AND SUPPLY OF A NEW PHARMACEUTICAL FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY

Leading Australian pharmaceutical firm, Phebra Pty Ltd, is pleased to announce it has signed an agreement with Michigan-based Phrixus Pharmaceuticals Inc. ('Phrixus') to manufacture and distribute (Carmeseal-MD™) and to assist Phrixus with its clinical trials. This new drug from Phrixus is expected to aid Duchenne muscular dystrophy (DMD) in patients suffering cardiac and respiratory deficits.

DMD is a crippling, degenerative disease, primarily affecting boys and young men, leading to muscular weakness, respiratory distress and early death through heart failure.

The Phrixus compound is a small sterile preparation intended for daily subcutaneous administration. It is a unique speciality treatment for patients with DMD, which aims at modulating cellular damage and assisting with the stabilisation and preservation of the plasma membrane, which results from a loss of functional muscle dystrophin protein.

The effect of reducing muscle damage in key organs leads to an improved survival of these cells, which translates into improved function of the heart, the diaphragm and skeletal limb muscle for patients with DMD.

Announcing the agreement today, Phebra Chief Executive Officer, Dr Mal Eutick said: "Phebra is delighted to have concluded this agreement with Phrixus for the manufacture and distribution of this very important disease modifying, speciality drug."

"DMD is a progressive and devastating genetic disease and Phebra looks forward to working closely with Phrixus and the Duchenne muscular dystrophy communities to achieve favourable outcomes and improve the lives of those patients concerned."

"This latest agreement strengthens Phebra's commitment to pursuing the treatment of rare diseases in Australia and across the world."

About Phebra:

Phebra is an Australian based specialty pharmaceutical company which develops, manufactures and markets critical medicines in Australia and across the world.

At Phebra, we create critical medicines that save and improve lives.

Phebra media contact: Richard Lenarduzzi. +61 411 254 390